No GLP-1 Receptor Agonist is Currently Approved for MASLD in India
No GLP-1 receptor agonist has regulatory approval specifically for the treatment of MASLD in India. The only medication approved in India for MASLD is saroglitazar, which is a dual PPAR α/γ agonist, not a GLP-1 receptor agonist 1.
Current Regulatory Landscape
The Drug Controller General of India (DCGI) has approved saroglitazar for MASLD treatment, making it the first and currently only agent with this specific indication in India 1. This is distinct from approvals in other regions—for example, the U.S. FDA recently approved resmetirom (a thyroid hormone receptor-beta agonist) as the first MASLD treatment in the United States 1.
GLP-1 Receptor Agonists: Not Approved as MASLD-Targeted Therapy
According to the most recent 2024 EASL-EASD-EASO guidelines, GLP-1 receptor agonists cannot currently be recommended as MASH-targeted therapies due to the absence of formal demonstration of histological improvement in large, well-conducted phase III trials 2. This represents a strong recommendation with 98% consensus.
However, GLP-1 RAs Should Still Be Used When Indicated
Despite lacking approval for MASLD specifically, GLP-1 receptor agonists are safe to use in MASH (including compensated cirrhosis) and should be used for their respective approved indications—namely type 2 diabetes and obesity—as their use improves cardiometabolic outcomes 2. This is a strong recommendation with 98% consensus.
Clinical Reasoning for GLP-1 RA Use in MASLD Patients
While not approved as liver-directed therapy, GLP-1 receptor agonists offer substantial benefits:
- Cardiometabolic protection: Cardiovascular disease is the leading cause of death in MASLD patients, and GLP-1 RAs have proven cardiovascular risk reduction 3
- Weight loss benefits: In cases of substantial weight loss induced by GLP-1 RAs, hepatic histological benefit could be expected, though this has not been extensively documented 2
- Safety profile: GLP-1 receptor agonists can be used in adults with Child-Pugh class A cirrhosis according to their approved indications 2
Emerging Evidence (Not Yet Regulatory Approval)
Recent trials show promising results:
- Semaglutide achieved 62.9% MASH resolution vs. 34.3% placebo in F2-F3 disease 3
- Tirzepatide demonstrated 44-62% MASH resolution vs. 10% placebo 3
- Liraglutide showed 39% steatohepatitis resolution vs. 9% placebo in the LEAN trial 3
However, these data have not translated to regulatory approval for MASLD indication in India or elsewhere yet.
Practical Approach for Indian Clinicians
For patients with MASLD in India:
If the patient has type 2 diabetes or obesity: Use GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) for these approved indications, which will provide cardiometabolic benefits and likely hepatic benefits through weight loss 2
If seeking MASLD-specific therapy: Saroglitazar is the only approved option in India 1
Avoid positioning GLP-1 RAs as "liver drugs": They should be prescribed for diabetes or obesity management, with liver benefits as a secondary outcome
Key Caveat
The distinction between "approved for MASLD" versus "safe and beneficial to use in patients with MASLD" is critical. GLP-1 receptor agonists fall into the latter category—they should absolutely be used when diabetes or obesity indications exist, but they are not formally approved MASLD treatments in India or globally.